/C O R R E C T I O N -- Suanfarma/ English
Pere Mañé Appointed as New CEO of Suanfarma
MADRID, April 22, 2025 /CNW/ -- Suanfarma, a global company specializing in the development, production, and commercialization of active pharmaceutical ingredients (APIs) and high-value CDMO services for the health industry, has announced the appointment of Pere Mañé Godina as its new Chief Executive Officer (CEO). This marks the beginning of a new chapter for the company, focused on industrial consolidation, sustainable innovation, and global expansion.
With a career spanning more than 30 years, Pere has held technical and strategic executive positions at leading pharmaceutical companies such as Uquifa, Boehringer Ingelheim, and Esteve Química (Esteve Group). His experience ranges from technical and operational roles to executive positions such as General Manager and Group Chief Industrial Operations Officer.
Most recently, Pere played a key role in the industrial transformation of Esteve, positioning its chemical division as a global benchmark. Under his leadership, the company was recognized as CDMO of the Year – Small Molecules at the 2025 CDMO Leadership Awards, one of the industry's most prestigious honors.
This appointment aligns with Suanfarma's long-term strategic vision. Carlos Alonso, interim CEO since October 2024, will ensure a smooth transition and will remain with the company as Executive Chairman:
"We are confident that Pere's deep sector knowledge, strategic mindset, and leadership experience will be instrumental in strengthening Suanfarma's market position and continuing to deliver high-value solutions to our customers and partners."
Pere's arrival brings decisive momentum to Suanfarma's growth journey. His focus on operational excellence, advanced CDMO capabilities, and strong strategic partnerships will guide the company through its next phase with the following objectives:
Streamlining industrial operations and integrating new technologies
Strengthening relationships with global clients and key suppliers
Accelerating international expansion
Fostering a culture of innovation and sustainability
In the words of Pere Mañé Godina, "Suanfarma has all the elements to lead the future of the industry: a solid foundation, a strong industrial platform, and a high-value international network supported by an exceptional team. I'm excited to begin this new chapter and work together to keep delivering innovative, efficient, and sustainable solutions to our clients."
Founded in 1993, Suanfarma is a B2B partner in the life sciences sector, committed to health and innovation through the sustainable development, manufacturing, and distribution of high-quality pharmaceutical ingredients. With presence in over 70 countries, it has been part of the healthcare-focused investment firm Archimed since 2021.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
11 minutes ago
- Cision Canada
ORMCO™ UNVEILS SPARK™ STAGERX™, THE NEXT EVOLUTION OF ALIGNER TREATMENT PLANNING
- Enhanced Treatment Accuracy Through a Powerful, Visual, and Streamlined Modular Workflow - BREA, Calif., Aug. 21, 2025 /CNW/ -- Ormco Corporation, providing innovative products, solutions, and education to the orthodontic community for over 60 years, today announces the launch of Spark™ StageRx™, a groundbreaking visual workflow revolutionizing aligner treatment planning. This new tool not only improves clinical communication but also brings more efficiency to the doctor's workflow, enhancing treatment accuracy through standardized and modular protocols. Spark™ StageRx™ - enhanced treatment accuracy through a powerful, visual, and streamlined modular workflow. Post this "StageRx enables the peer-to-peer sharing of aligner protocols, fostering a vibrant community of aligner knowledge among practitioners, and 89% of doctors stating they are likely to recommend StageRx to their colleagues. 1 Based on initial customer feedback, we are seeing this platform make a meaningful impact in practices," said Jay Issa, Vice President, Portfolio Management and Global Marketing, Ormco. "It comes with Spark Aligner protocols created by top global aligner experts, making it a helpful tool for both novice and advanced aligner doctors." Key Features & Benefits of Spark StageRx: Standardize communication with designers in a non-textual format. 84% of doctors agree StageRx has improved communication with treatment designers.¹ Protocol library provides select Spark standard and expert protocols, as well as your own creation for easy access and reuse. Visualize your setup with an easy drag and drop staging workspace. "This has completely transformed our clear aligner treatment planning process. It's visual, intuitive, and easy to use—you simply drag and drop," said Dr. Nadia Nizam. 2"The platform enables a smarter, more collaborative workflow by eliminating design inconsistencies and standardizing communication, all without sacrificing customization. My team can tailor treatment for each patient by modifying or adding steps, which are then submitted directly through the Spark DTX portal—ensuring both precision and consistency." For more information on Spark StageRx, visit Orthodontic Software | Spark™ Clear Aligner System | Ormco. About the Spark™ Clear Aligner System Spark Aligners are manufactured by Ormco, a global leader in innovative orthodontic products with 60 years of expertise, R&D, and high manufacturing standards. Ormco has helped doctors treat more than 20 million patients in more than 140 countries. Spark Approver Software is designed to give doctors more control and flexibility, while Spark's advanced aligner technology and TruGEN™ material provide more sustained force retention. Compared to the leading aligner brand and when contacting the same tooth, the Spark Aligner has 18% better surface contact with the tooth and is also designed to be more clear and more comfortable than the leading aligner brand and stain less than the leading aligner material -- which may be why 100% of patients recently surveyed said they would recommend Spark Aligners to a friend. 3 For more information about Spark Aligners, visit About Ormco Envista is a global family of more than 30 trusted dental brands, including Ormco, Nobel Biocare, DEXIS, and Kerr, united by a shared purpose: to partner with professionals to improve lives. Ormco, headquartered in Brea, Calif., is a global leader and innovator of orthodontic products and solutions to help enhance the lives of its customers and their patients. For more than 60 years, Ormco has partnered with the orthodontic community to help create over 20 million smiles in over 140 countries. Distinguished products range from twin brackets (Symetri™ Clear Brackets, Titanium Orthos™, and Mini Diamond™) to pioneering self-ligating appliances with the Damon™ System (including Damon Ultima™ System and Damon™ Clear2). The Spark™ Clear Aligner System is designed to meet the needs of the orthodontist with the TruGEN™ material and Approver Software. Ormco's Insignia™ Advanced Smile Design™ provides an all-inclusive customized indirect bonding solution for efficiency through personalization. From personalized service to professional education programs and marketing support, Ormco is committed to helping orthodontists achieve their clinical and practice management objectives. Connect on Facebook at and LinkedIn at 1 Data on file. Based on a survey of doctors completed in February 2025. 2 Dr. Nadia Nizam is a paid consultant for Ormco. The opinions expressed are those of the doctor. Ormco is a medical device manufacturer and does not dispense medical advice. Clinicians should use their own judgment in treating their patients. 3 Marketing Confirmation Study-Data on File with Ormco Corporation.
Cision Canada
11 minutes ago
- Cision Canada
Binti Launches First-of-its-Kind "AI for Social Services" Offering with Anthropic, Unleashing AI to Its Customer Base of Agencies Serving 46% of Child Welfare Across the U.S.
Collaboration falls under Anthropic's "AI for Good" focus. Through embedding Claude, Binti will help social workers save administrative time and focus on working with children and families SAN FRANCISCO, Aug. 21, 2025 /CNW/ -- Binti, the company that is the leader in building software to support social workers and improve outcomes in the child welfare system, announced it's now collaborating with Anthropic to extend its reach across government agencies in the US with Artificial Intelligence (AI). The mission-driven technology company currently serves over 550 agencies in 36 states and the District of Columbia with its SaaS offerings, reaching agencies serving 46% of child welfare in the U.S, and is now expanding with its new AI offering, powered by Anthropic's Claude. Many social workers spend more than 50% of their time on administrative tasks, which leads to social worker burnout and not enough time with children and families. Binti and Anthropic are collaborating to launch AI tools that streamline much of this administrative work. Binti is careful not to use AI to make any decisions or recommendations. Social workers review and approve what is drafted by AI, ensuring there is human review of all work. New features of Binti AI include: Binti Form and Case Note Completion: Social workers can record meetings with families, with their permission. The recording fills out a draft of the social workers' paperwork or case notes for them, saving hours of administrative time. Social workers can also upload handwritten notes to fill out a draft of their paperwork for them. Chat with Binti AI: Social workers can chat with their case using AI to search through hundreds of pages of forms, case notes, case data, and agency policies to quickly get answers. "We're thrilled to collaborate with Anthropic on safe use of AI and leverage its LLM as we expand our offerings to social workers across the country," said CEO and Co-founder of Binti, Felicia Curcuru. "We have a strong presence across local and state government agencies, serving over 46% of children in care nationwide with our software products, and know that by furthering our offerings with AI, powered by Claude, we will be able to save social workers even more time, and empower them to work more closely with families and children. The ultimate goal is to help every child have a family and a fair chance at life." Binti is uniquely positioned as a trusted partner to sell into government agencies today and show immediate ROI with its quick deployment. "When we founded Anthropic, we believed AI could transform lives in meaningful ways," said Dario Amodei, CEO and co-founder of Anthropic. "Seeing Binti help connect children with loving families faster by cutting through months of paperwork is exactly the real-world impact we hoped to enable." Binti and Anthropic did a pilot launch with 20 child welfare agencies in recent months. The positive results are leading them to open up broadly to all child welfare agencies going forward. Workers have reported saving hours of administrative time every week after using the AI tools. For more information on Binti's offerings, visit About Binti Binti is a mission-driven technology company that builds software to improve the child welfare system in America. Binti has launched several products across 550+ child welfare agencies in 36 states, serving 46% of the country. Binti has served over 100,000 families and over 12,000 social workers. Binti was founded in 2017 and has raised over $60M from top investors, including Founders Fund, First Round Capital, Michael Dell, and others. For more information visit
Cision Canada
11 minutes ago
- Cision Canada
Health Canada grants marketing authorization for an additional indication of Bayer's NUBEQA® (darolutamide) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) Français
Today's marketing authorization is based on recent results from the Phase III ARANOTE trial and broadens the indication profile of darolutamide in metastatic hormone-sensitive prostate cancer (mCSPC), enabling its use in combination with ADT, with or without chemotherapy (docetaxel) MISSISSAUGA, ON, Aug. 21, 2025 /CNW/ - Bayer Inc. is pleased to announce that Health Canada has granted marketing authorization for its oral androgen receptor inhibitor (ARi) NUBEQA ® (darolutamide) 1 for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC). This marketing authorization is based on results from the pivotal 2 Phase III ARANOTE trial, which showed that darolutamide plus ADT reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001) in patients with mCSPC. With this additional marketing authorization, darolutamide plus ADT is the first and only ARi indicated in Canada for the treatment of adult patients with mCSPC, either with or without docetaxel. In addition, darolutamide is approved for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. "This latest authorization reaffirms NUBEQA's role as a therapy for men with prostate cancer," said Shurjeel Choudhri, Senior Vice President and Head of Medical and Scientific Affairs for Bayer Canada. "We extend our thanks to the scientists, doctors, patients, and their families for their contributions that allowed us to offer this new treatment option for metastatic castration-sensitive prostate cancer." "Clinical data from the ARANOTE trial showed that darolutamide is both efficacious and well tolerated as a combination therapy with androgen-deprivation therapy," said Fred Saad, M.D., Professor and Chairman of Surgery and Director of Genitourinary Oncology at the University of Montreal Hospital Center (CHUM), and Principal Investigator of the ARANOTE trial. "Today's approval further expands options for how physicians can use Nubeqa in the treatment of mCSPC, giving them greater flexibility in choosing treatment plans for their patients." In Canada, prostate cancer is the most commonly diagnosed cancer among men, with an incidence rate of 119.7 cases per 100,000 men annually. 3 Among those who are diagnosed, there is a portion of patients who will present with metastatic castration-sensitive prostate cancer (mCSPC), which may occur either de novo (newly diagnosed with metastatic disease) or as metachronous (recurrent disease following treatment for localized prostate cancer). In Canada, approximately 8.6% of all new prostate cancer cases are diagnosed as de novo mCSPC. 4 Prognosis varies by disease stage, and while overall survival for prostate cancer is high, the 5-year net survival rate for patients with stage IV metastatic prostate cancer is approximately 41%, highlighting the need for optimized treatment strategies in this population. ² "Prostate cancer continues to have a significant impact on men and their families in Canada, with incidence and mortality rates that remain unacceptably high," said Dr. Stuart Edmonds, Executive Vice President for Mission, Research and Advocacy at the Canadian Cancer Society. "Bringing more treatments to patients faster offers new hope, greater choice, and the potential for improved outcomes." Darolutamide is developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company. About the ARANOTE Trial The ARANOTE trial is a randomized, double-blind, placebo-controlled Phase III study designed to assess the efficacy and safety of darolutamide plus ADT in patients with mCSPC. 669 patients were randomized 2:1 to receive 600 mg of darolutamide twice daily or matching placebo in addition to ADT. The primary endpoint of this study is rPFS (radiographic progression-free survival), measured as time from randomization to date of first documented radiological progressive disease or death due to any cause, whichever occurs first. Secondary endpoints include overall survival (time to death from any cause), time to metastatic castration-resistant prostate cancer, time to initiation of subsequent systemic anti-cancer therapy, time to prostate-specific antigen (PSA) progression, PSA undetectable rates, time to pain progression, and safety assessments. Results from the Phase III ARANOTE trial were presented at ESMO 2024 and published in The Journal of Clinical Oncology. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people, and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to Journal of Clinical Oncology: Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2023. Toronto, Ontario: Canadian Cancer Society; 2023. Canadian Cancer Society. Survival statistics for prostate cancer. 2021; Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. ___________________ SOURCE Bayer Inc.
